Socioeconomic status and use of obesogenic and anti-obesity medications in the United States: A population-based study.
Disparities
Obesity
Obesogenic medications
Pharmacoequity
Socioeconomic status
Journal
Lancet regional health. Americas
ISSN: 2667-193X
Titre abrégé: Lancet Reg Health Am
Pays: England
ID NLM: 9918232503006676
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
entrez:
5
8
2022
pubmed:
6
8
2022
medline:
6
8
2022
Statut:
ppublish
Résumé
The Endocrine Society Clinical Practice Guidelines recommend the avoidance of medications that may cause weight gain (i.e., obesogenic medications) in individuals with overweight or obesity. Obesity disproportionately affects people with lower socioeconomic status (SES); however, it is unknown whether the use of obesogenic medications differs by SES. We included adults with overweight or obesity and used prescription medications from 2009-2018 of the US National Health and Nutrition Examination Survey. We examined the associations between a composite measure of SES and use of obesogenic medications and anti-obesity medications. The composite SES included <high school education (1 point), household income below federal poverty level (1 point), no insurance (2 points), and public health insurance only (1 point). We defined 3 composite SES groups (0 [high], 1 [intermediate], and ≥2 points [low]). Among 10,673 US adults with overweight or obesity, 20.0% had low SES. Use of obesogenic medications was common (37.7%). Low (vs. high) SES was associated with greater obesogenic medication use, independent of demographic characteristics, prescription medication burden, and comorbidities (OR 1.3 [1.2-1.5]). Among 12,133 eligible participants, utilization of anti-obesity medications was very low overall (0.5%) and within all SES groups (low 0.27%, intermediate 0.71, and high 0.65%). Our findings highlight common and modifiable risk factors for obesity. Clinicians should screen patient medications for those that may cause weight gain and increase adoption of anti-obesity medications, especially among adults living in low SES. The National Institute of Diabetes and Digestive and Kidney Disease (R01DK115534, K24HL155861, and K01DK121825).
Sections du résumé
Background
UNASSIGNED
The Endocrine Society Clinical Practice Guidelines recommend the avoidance of medications that may cause weight gain (i.e., obesogenic medications) in individuals with overweight or obesity. Obesity disproportionately affects people with lower socioeconomic status (SES); however, it is unknown whether the use of obesogenic medications differs by SES.
Methods
UNASSIGNED
We included adults with overweight or obesity and used prescription medications from 2009-2018 of the US National Health and Nutrition Examination Survey. We examined the associations between a composite measure of SES and use of obesogenic medications and anti-obesity medications. The composite SES included <high school education (1 point), household income below federal poverty level (1 point), no insurance (2 points), and public health insurance only (1 point). We defined 3 composite SES groups (0 [high], 1 [intermediate], and ≥2 points [low]).
Findings
UNASSIGNED
Among 10,673 US adults with overweight or obesity, 20.0% had low SES. Use of obesogenic medications was common (37.7%). Low (vs. high) SES was associated with greater obesogenic medication use, independent of demographic characteristics, prescription medication burden, and comorbidities (OR 1.3 [1.2-1.5]). Among 12,133 eligible participants, utilization of anti-obesity medications was very low overall (0.5%) and within all SES groups (low 0.27%, intermediate 0.71, and high 0.65%).
Interpretation
UNASSIGNED
Our findings highlight common and modifiable risk factors for obesity. Clinicians should screen patient medications for those that may cause weight gain and increase adoption of anti-obesity medications, especially among adults living in low SES.
Funding
UNASSIGNED
The National Institute of Diabetes and Digestive and Kidney Disease (R01DK115534, K24HL155861, and K01DK121825).
Identifiants
pubmed: 35928911
doi: 10.1016/j.lana.2022.100249
pmc: PMC9348594
mid: NIHMS1823940
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIDDK NIH HHS
ID : K01 DK121825
Pays : United States
Références
Best Pract Res Clin Endocrinol Metab. 2013 Apr;27(2):139-46
pubmed: 23731876
N Engl J Med. 2021 Jun 10;384(23):2219-2228
pubmed: 34107181
N Engl J Med. 2017 Jul 6;377(1):13-27
pubmed: 28604169
Diabetes Metab Syndr Obes. 2018 Aug 21;11:427-438
pubmed: 30174450
JAMA. 2021 Nov 9;326(18):1793-1794
pubmed: 34677579
J Prim Care Community Health. 2017 Jul;8(3):169-175
pubmed: 28606031
Sleep. 2014 Feb 01;37(2):343-9
pubmed: 24497662
Drugs Context. 2016 Mar 08;5:212291
pubmed: 27114740
BMC Med Res Methodol. 2019 Jul 17;19(1):153
pubmed: 31315574
Curr Diab Rep. 2015 Nov;15(11):95
pubmed: 26377742
Diabetes Care. 2020 Oct;43(10):2330-2332
pubmed: 32958616
Am J Kidney Dis. 2021 Mar;77(3):427-439
pubmed: 33075388
JAMA Netw Open. 2019 Dec 2;2(12):e1917995
pubmed: 31860105
JAMA Intern Med. 2020 Dec 1;180(12):1696-1699
pubmed: 32926091
Obesity (Silver Spring). 2014 Jul;22 Suppl 2:S5-39
pubmed: 24961825
Obesity (Silver Spring). 2020 Nov;28(11):2003-2009
pubmed: 33150743
J Clin Endocrinol Metab. 2015 Feb;100(2):363-70
pubmed: 25590213
J Fam Pract. 2016 Nov;65(11):780-788
pubmed: 28087864
Obesity (Silver Spring). 2022 Jan;30(1):229-239
pubmed: 34907655
JAMA Cardiol. 2018 Dec 1;3(12):1174-1182
pubmed: 30484833
BMC Public Health. 2016 Sep 13;16:975
pubmed: 27624540
Vital Health Stat 2. 2013 Sep;(161):1-24
pubmed: 25090154
Mayo Clin Proc. 2021 Dec;96(12):2991-3000
pubmed: 34728060
Lancet. 2015 Jun 13;385(9985):2400-9
pubmed: 25703111
J Psychiatr Res. 2012 Apr;46(4):540-8
pubmed: 22316639
Obesity (Silver Spring). 2018 Apr;26(4):665-671
pubmed: 29570250
Obesity (Silver Spring). 2018 Dec;26(12):1834-1840
pubmed: 30426721
Obesity (Silver Spring). 2020 Nov;28(11):2064-2072
pubmed: 33022115
J Endocrinol Invest. 2017 Nov;40(11):1165-1174
pubmed: 28660606
Lancet. 2016 May 7;387(10031):1947-56
pubmed: 26868660
Metabolism. 2019 Mar;92:121-135
pubmed: 30445141
Lancet Neurol. 2015 Dec;14(12):1206-18
pubmed: 26581971
Obesity (Silver Spring). 2019 May;27(5):716-723
pubmed: 31012292
J Clin Endocrinol Metab. 2015 Feb;100(2):342-62
pubmed: 25590212
Arch Intern Med. 2010 Jan 25;170(2):121-3
pubmed: 20101005
Int J Obes (Lond). 2019 Jun;43(6):1154-1163
pubmed: 30242239
JAMA. 2000 May 17;283(19):2579-84
pubmed: 10815125
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941